Edition:
United Kingdom

BIOLASE Inc (BIOL.OQ)

BIOL.OQ on NASDAQ Stock Exchange Capital Market

0.44USD
4:06pm GMT
Change (% chg)

$0.01 (+2.33%)
Prev Close
$0.43
Open
$0.44
Day's High
$0.46
Day's Low
$0.44
Volume
5,774
Avg. Vol
34,592
52-wk High
$1.57
52-wk Low
$0.32

Latest Key Developments (Source: Significant Developments)

Biolase Files For Possible Resale Of Up To 21.9 Mln Shares Of Common Stock By Selling Stockholders
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Biolase Inc ::BIOLASE INC FILES FOR POSSIBLE RESALE OF UP TO 21.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Biolase reports Q3 non-GAAP loss per share $0.05
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Biolase Inc :Biolase reports 2017 third quarter and nine-month results.Q3 non-GAAP loss per share $0.05.Q3 loss per share $0.06.Q3 revenue rose 18 percent to $10.8 million.  Full Article

Biolase appoints Richard Lanman to board of directors
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Biolase Inc ::Biolase appoints Richard B. Lanman to board of directors.Biolase - ‍Lanman replaces outgoing director Fredrick Moll​.  Full Article

Biolase Q2 loss per share $0.06
Monday, 1 Aug 2016 

Biolase Inc : Biolase Reports 2016 Second Quarter And Six-Month results . Q2 revenue rose 16 percent to $13.8 million .Q2 loss per share $0.06.  Full Article

Biolase to raise $10 mln in convertible preferred private placement
Monday, 1 Aug 2016 

Biolase Inc : Biolase to raise $10 million from institutional and individual investors in convertible preferred private placement .Has agreed to sell an aggregate of 88,494 shares of its convertible preferred stock at a per share price of $113.00.  Full Article

Biolase reports Q1 loss per share $0.07
Monday, 9 May 2016 

Biolase Inc : Biolase reports 2016 first quarter results . Q1 loss per share $0.07 .Q1 revenue rose 1.4 percent to $11 million.  Full Article

BRIEF-Biolase Releases Statement‍ In Response To Cao Group Litigation​

* RELEASED STATEMENT‍ IN RESPONSE TO CAO GROUP LITIGATION​ Source text for Eikon: Further company coverage: